



## Clinical trial results:

**A safety, tolerability, pharmacokinetics and efficacy study of RO7049389 in: (1) single- (with or without food) and multiple- (with midazolam) ascending doses in healthy volunteers; (2) patients chronically infected with hepatitis B virus (3) patients with chronic hepatitis B**

### Summary

EudraCT number	2019-001139-30
Trial protocol	BG
Global end of trial date	16 March 2022

### Results information

Result version number	v1 (current)
This version publication date	31 March 2023
First version publication date	31 March 2023

### Trial information

#### Trial identification

Sponsor protocol code	YP39364
-----------------------	---------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02952924
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Hoffmann-La Roche
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, 4070
Public contact	Medical Communications, Hoffmann-La Roche, +41 61 688 1111, global.roche.genentechtrials@roche.com
Scientific contact	Medical Communications, Hoffmann-La Roche, +41 61 688 1111, global.roche.genentechtrials@roche.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 March 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	16 March 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This study was a multicenter, three-part study. Parts 1 and 2 were randomized, investigator- and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7049389 following oral administration in healthy volunteers and chronic HBV infected participants. Part 3 was a non-randomized, non-controlled, open-label part to assess the efficacy and safety of RO7049389 when administered in combination with standard-of-care therapies for up to 48 weeks in nucleos(t)ide (NUC)-suppressed and treatment-naïve chronic hepatitis B (CHB) participants.

Protection of trial subjects:

Participants were required to sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 December 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 1
Country: Number of subjects enrolled	Bulgaria: 10
Country: Number of subjects enrolled	China: 18
Country: Number of subjects enrolled	Hong Kong: 22
Country: Number of subjects enrolled	New Zealand: 107
Country: Number of subjects enrolled	Singapore: 5
Country: Number of subjects enrolled	Thailand: 15
Country: Number of subjects enrolled	Taiwan: 14
Worldwide total number of subjects	192
EEA total number of subjects	10

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	192
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Healthy volunteers (Part 1); participants with chronic hepatitis B virus (Part 2); treatment-naïve or treatment-suppressed participants with chronic hepatitis B virus

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Parts 1a and 1b: Single ascending dose (SAD) Placebo

Arm description:

Healthy volunteers (HVs) received a single dose of placebo under fasted (Part 1a) or fed (Part 1b) conditions.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Single dose administered orally

<b>Arm title</b>	Part 1c: Multiple ascending dose (MAD) Placebo
------------------	------------------------------------------------

Arm description:

HVs received placebo either once-daily (QD) or twice-daily (BID) for 13 days, followed by a single dose on Day 14.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Administered orally once-daily (QD) or twice-daily (BID) for 13 days, followed by a single dose on Day 14.

<b>Arm title</b>	Part 2: Proof-of-Mechanism (POM) Placebo
------------------	------------------------------------------

Arm description:

Participants with chronic hepatitis B virus (CHB) infection received placebo once daily (QD) or twice daily (BID) for 27 days, followed by a single dose on Day 28.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Administered orally once daily (QD) or twice daily (BID) for 27 days, followed by a single dose on Day 28.	
<b>Arm title</b>	Part 1a: SAD Cohort 1
Arm description:	
HVs received a single dose of 150 mg of RO7049389 under fasted conditions.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Single oral dose of 150 mg of RO7049389 under fasted conditions.	
<b>Arm title</b>	Part 1a and Part 1b: SAD Cohort 2 (food effect)
Arm description:	
Part 1a: HVs received a single dose of 450 mg of RO7049389 under fasted conditions.	
Part 1b: HVs received a single dose of 450 mg of RO7049389 on Day 16 after a standard US FDA-recommended high-fat high-calorie meal.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Part 1a: Single oral dose of 450 mg of RO7049389 under fasted conditions.	
Part 1b: Single oral dose of 450 mg of RO7049389 on Day 16 after a standard US FDA-recommended high-fat high-calorie meal.	
<b>Arm title</b>	Part 1a: SAD Cohort 3
Arm description:	
HVs received a single dose of 1000 mg of RO7049389 under fasted conditions.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Single oral dose of 1000 mg of RO7049389 under fasted conditions.	
<b>Arm title</b>	Part 1a: SAD Cohort 4
Arm description:	
HVs received a single dose of 2000 mg of RO7049389 under fasted conditions.	
Arm type	Experimental

Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Single oral dose of 2000 mg of RO7049389 under fasted conditions.	
<b>Arm title</b>	Part 1a: SAD Cohort 5
Arm description:	
HVs received a single dose of 1000 mg of RO7049389 under fasted conditions.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Single oral dose of 1000 mg of RO7049389 under fasted conditions.	
<b>Arm title</b>	Part 1a: SAD Cohort 6
Arm description:	
HVs received a single dose of 2500 mg of RO7049389 under fasted conditions.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
Single oral dose of 2500 mg of RO7049389 under fasted conditions.	
<b>Arm title</b>	Part 1c: MAD Cohort 1
Arm description:	
HVs received 200 mg of RO7049389 BID under fasted conditions for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details:	
200 mg of RO7049389 BID administered orally under fasted conditions for 13 days, followed by a single dose on Day 14.	
Investigational medicinal product name	Midazolam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use
Dosage and administration details:	
Single dose of 100 micrograms administered orally on Day -1 and Day 14.	
<b>Arm title</b>	Part 1c: MAD Cohort 2

**Arm description:**

HVs received 200 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.

Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

**Dosage and administration details:**

200 mg of RO7049389 administered orally BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14.

Investigational medicinal product name	Midazolam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

**Dosage and administration details:**

Single dose of 100 micrograms administered orally on Day -1 and Day 14.

<b>Arm title</b>	Part 1c: MAD Cohort 3
------------------	-----------------------

**Arm description:**

HVs received 400 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.

Arm type	Experimental
Investigational medicinal product name	Midazolam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

**Dosage and administration details:**

Single dose of 100 micrograms administered orally on Day -1 and Day 14.

Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

**Dosage and administration details:**

400 mg of RO7049389 administered orally BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14.

<b>Arm title</b>	Part 1c: MAD Cohort 4
------------------	-----------------------

**Arm description:**

HVs received 800 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.

Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details: 800 mg of RO7049389 administered orally BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14.	
Investigational medicinal product name	Midazolam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use
Dosage and administration details: Single dose of 100 micrograms administered orally on Day -1 and Day 14.	
<b>Arm title</b>	Part 1c: MAD Cohort 5
Arm description: HVs received 600 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 600 mg of RO7049389 administered orally BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14.	
Investigational medicinal product name	Midazolam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use
Dosage and administration details: Single dose of 100 micrograms administered orally on Day -1 and Day 14.	
<b>Arm title</b>	Part 2: POM Cohort 1
Arm description: Participants with CHB received 200 mg of RO7049389 BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 200 mg of RO7049389 administered orally BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.	
<b>Arm title</b>	Part 2: POM Cohort 2
Arm description: Participants with CHB received 400 mg of RO7049389 BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.	
Arm type	Experimental

Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 400 mg of RO7049389 administered orally BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.	
<b>Arm title</b>	Part 2: POM Cohort 3
Arm description: Participants with CHB received 600 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 600 mg of RO7049389 administered orally QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
<b>Arm title</b>	Part 2: POM Cohort 4
Arm description: Participants with CHB received 1000 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 1000 mg of RO7049389 administered orally QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
<b>Arm title</b>	Part 2: POM Cohort 5
Arm description: Participants with CHB received 200 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 200 mg of RO7049389 administered orally QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
<b>Arm title</b>	Part 3: Cohort A
Arm description: Nucleos(t)ide (NUC)-suppressed CHB participants received 600 mg of RO7049389 QD under fasted conditions in addition to an NUC (administered per local SoC) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.	
Arm type	Experimental

Investigational medicinal product name	NUC (entecavir, tenofovir alafenamide, or tenofovir disoproxil fumarate)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Administered per local label for 48 weeks during the study treatment period, with or without an additional 24 weeks.

Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

RO7049389 administered orally for 48 weeks.

<b>Arm title</b>	Part 3: Cohort B
------------------	------------------

Arm description:

Treatment-naïve immune-active CHB participants 600 mg of RO7049389 QD under fasted conditions for 4 weeks, followed by RO7049389 + NUC (administered per local SoC) for an additional 44 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.

Arm type	Experimental
Investigational medicinal product name	NUC (entecavir, tenofovir alafenamide, or tenofovir disoproxil fumarate)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Administered per local label for 44 weeks during the study treatment period, with or without an additional 24 weeks.

Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

RO7049389 administered orally for 48 weeks.

<b>Arm title</b>	Part 3: Cohort C
------------------	------------------

Arm description:

Treatment-naïve immune-active CHB participants received 600 mg of RO7049389 QD under fasted conditions + NUC + pegylated interferon (Peg-IFN) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.

Arm type	Experimental
Investigational medicinal product name	RO7049389
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

RO7049389 administered orally for 48 weeks.

Investigational medicinal product name	Pegylated interferon
Investigational medicinal product code	
Other name	PEG-IFN
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered per local label for 48 weeks

Investigational medicinal product name	NUC (entecavir, tenofovir alafenamide, or tenofovir disoproxil fumarate)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Administered per local label for 48 weeks during the study treatment period, with or without an additional 24 weeks.

Number of subjects in period 1	Parts 1a and 1b: Single ascending dose (SAD) Placebo	Part 1c: Multiple ascending dose (MAD) Placebo	Part 2: Proof-of-Mechanism (POM) Placebo
Started	11	10	6
Completed	11	10	6
Not completed	0	0	0
Participant unable to adhere to study schedule	-	-	-
Noncompliance with study drug	-	-	-
Participant refused to adhere to study protocol	-	-	-
Protocol deviation	-	-	-

Number of subjects in period 1	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3
Started	3	6	3
Completed	3	6	3
Not completed	0	0	0
Participant unable to adhere to study schedule	-	-	-
Noncompliance with study drug	-	-	-
Participant refused to adhere to study protocol	-	-	-
Protocol deviation	-	-	-

Number of subjects in period 1	Part 1a: SAD Cohort 4	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6
Started	6	6	6
Completed	6	6	6
Not completed	0	0	0
Participant unable to adhere to study schedule	-	-	-
Noncompliance with study drug	-	-	-

Participant refused to adhere to study protocol	-	-	-
Protocol deviation	-	-	-

Number of subjects in period 1	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3
Started	6	7	7
Completed	6	7	7
Not completed	0	0	0
Participant unable to adhere to study schedule	-	-	-
Noncompliance with study drug	-	-	-
Participant refused to adhere to study protocol	-	-	-
Protocol deviation	-	-	-

Number of subjects in period 1	Part 1c: MAD Cohort 4	Part 1c: MAD Cohort 5	Part 2: POM Cohort 1
Started	6	6	6
Completed	6	6	6
Not completed	0	0	0
Participant unable to adhere to study schedule	-	-	-
Noncompliance with study drug	-	-	-
Participant refused to adhere to study protocol	-	-	-
Protocol deviation	-	-	-

Number of subjects in period 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Started	6	6	7
Completed	6	6	6
Not completed	0	0	1
Participant unable to adhere to study schedule	-	-	-
Noncompliance with study drug	-	-	-
Participant refused to adhere to study protocol	-	-	1
Protocol deviation	-	-	-

Number of subjects in period 1	Part 2: POM Cohort 5	Part 3: Cohort A	Part 3: Cohort B
Started	6	32	10
Completed	6	31	10
Not completed	0	1	0
Participant unable to adhere to study schedule	-	-	-
Noncompliance with study drug	-	-	-
Participant refused to adhere to study protocol	-	-	-
Protocol deviation	-	1	-

Number of subjects in period 1	Part 3: Cohort C
--------------------------------	------------------

Started	30
Completed	28
Not completed	2
Participant unable to adhere to study schedule	1
Noncompliance with study drug	1
Participant refused to adhere to study protocol	-
Protocol deviation	-

## Baseline characteristics

### Reporting groups

Reporting group title	Parts 1a and 1b: Single ascending dose (SAD) Placebo
Reporting group description: Healthy volunteers (HVs) received a single dose of placebo under fasted (Part 1a) or fed (Part 1b) conditions.	
Reporting group title	Part 1c: Multiple ascending dose (MAD) Placebo
Reporting group description: HVs received placebo either once-daily (QD) or twice-daily (BID) for 13 days, followed by a single dose on Day 14.	
Reporting group title	Part 2: Proof-of-Mechanism (POM) Placebo
Reporting group description: Participants with chronic hepatitis B virus (CHB) infection received placebo once daily (QD) or twice daily (BID) for 27 days, followed by a single dose on Day 28.	
Reporting group title	Part 1a: SAD Cohort 1
Reporting group description: HVs received a single dose of 150 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1a and Part 1b: SAD Cohort 2 (food effect)
Reporting group description: Part 1a: HVs received a single dose of 450 mg of RO7049389 under fasted conditions. Part 1b: HVs received a single dose of 450 mg of RO7049389 on Day 16 after a standard US FDA-recommended high-fat high-calorie meal.	
Reporting group title	Part 1a: SAD Cohort 3
Reporting group description: HVs received a single dose of 1000 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1a: SAD Cohort 4
Reporting group description: HVs received a single dose of 2000 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1a: SAD Cohort 5
Reporting group description: HVs received a single dose of 1000 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1a: SAD Cohort 6
Reporting group description: HVs received a single dose of 2500 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1c: MAD Cohort 1
Reporting group description: HVs received 200 mg of RO7049389 BID under fasted conditions for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Reporting group title	Part 1c: MAD Cohort 2
Reporting group description: HVs received 200 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Reporting group title	Part 1c: MAD Cohort 3
Reporting group description: HVs received 400 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Reporting group title	Part 1c: MAD Cohort 4
Reporting group description: HVs received 800 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	

Reporting group title	Part 1c: MAD Cohort 5
Reporting group description: HVs received 600 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Reporting group title	Part 2: POM Cohort 1
Reporting group description: Participants with CHB received 200 mg of RO7049389 BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.	
Reporting group title	Part 2: POM Cohort 2
Reporting group description: Participants with CHB received 400 mg of RO7049389 BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.	
Reporting group title	Part 2: POM Cohort 3
Reporting group description: Participants with CHB received 600 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Reporting group title	Part 2: POM Cohort 4
Reporting group description: Participants with CHB received 1000 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Reporting group title	Part 2: POM Cohort 5
Reporting group description: Participants with CHB received 200 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Reporting group title	Part 3: Cohort A
Reporting group description: Nucleos(t)ide (NUC)-suppressed CHB participants received 600 mg of RO7049389 QD under fasted conditions in addition to an NUC (administered per local SoC) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.	
Reporting group title	Part 3: Cohort B
Reporting group description: Treatment-naïve immune-active CHB participants 600 mg of RO7049389 QD under fasted conditions for 4 weeks, followed by RO7049389 + NUC (administered per local SoC) for an additional 44 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.	
Reporting group title	Part 3: Cohort C
Reporting group description: Treatment-naïve immune-active CHB participants received 600 mg of RO7049389 QD under fasted conditions + NUC + pegylated interferon (Peg-IFN) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.	

Reporting group values	Parts 1a and 1b: Single ascending dose (SAD) Placebo	Part 1c: Multiple ascending dose (MAD) Placebo	Part 2: Proof-of- Mechanism (POM) Placebo
Number of subjects	11	10	6
Age categorical Units: Subjects			
Adults (18-64 years)	11	10	6
Age Continuous Units: years			
arithmetic mean	26.1	25.2	43.5
standard deviation	± 8.4	± 4.9	± 6.4

Sex: Female, Male Units: Participants			
Female	1	0	3
Male	10	10	3
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	1	5
Native Hawaiian or Other Pacific Islander	0	1	1
Black or African American	1	0	0
White	9	7	0
More than one race	0	0	0
Unknown or Not Reported	0	1	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1	2	0
Not Hispanic or Latino	10	8	6
Unknown or Not Reported	0	0	0

Reporting group values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3
Number of subjects	3	6	3
Age categorical Units: Subjects			
Adults (18-64 years)	3	6	3
Age Continuous Units: years			
arithmetic mean	32.7	27.3	28.7
standard deviation	± 10.1	± 7.6	± 13.6
Sex: Female, Male Units: Participants			
Female	0	0	0
Male	3	6	3
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	0
Native Hawaiian or Other Pacific Islander	2	0	0
Black or African American	0	0	0
White	1	5	3
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	3	6	2
Unknown or Not Reported	0	0	0

Reporting group values	Part 1a: SAD Cohort 4	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6
------------------------	-----------------------	-----------------------	-----------------------

Number of subjects	6	6	6
Age categorical			
Units: Subjects			
Adults (18-64 years)	6	6	6
Age Continuous			
Units: years			
arithmetic mean	26.7	26.7	30.5
standard deviation	± 4.7	± 13.5	± 7.0
Sex: Female, Male			
Units: Participants			
Female	0	0	0
Male	6	6	6
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	3	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	6	3	6
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	2
Not Hispanic or Latino	6	6	4
Unknown or Not Reported	0	0	0

<b>Reporting group values</b>	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3
Number of subjects	6	7	7
Age categorical			
Units: Subjects			
Adults (18-64 years)	6	7	7
Age Continuous			
Units: years			
arithmetic mean	25.5	23.9	26.7
standard deviation	± 4.5	± 2.8	± 3.8
Sex: Female, Male			
Units: Participants			
Female	0	0	0
Male	6	7	7
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	0	3
Native Hawaiian or Other Pacific Islander	1	0	0
Black or African American	0	0	0
White	4	7	4
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	1	1
Not Hispanic or Latino	6	6	6
Unknown or Not Reported	0	0	0

<b>Reporting group values</b>	Part 1c: MAD Cohort 4	Part 1c: MAD Cohort 5	Part 2: POM Cohort 1
Number of subjects	6	6	6
Age categorical			
Units: Subjects			
Adults (18-64 years)	6	6	6
Age Continuous			
Units: years			
arithmetic mean	28.8	28.3	40.2
standard deviation	± 11.1	± 5.8	± 8.3
Sex: Female, Male			
Units: Participants			
Female	0	0	1
Male	6	6	5
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	1	5
Native Hawaiian or Other Pacific Islander	1	0	0
Black or African American	0	0	0
White	3	4	1
More than one race	1	0	0
Unknown or Not Reported	0	1	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	1	0
Not Hispanic or Latino	6	5	6
Unknown or Not Reported	0	0	0

<b>Reporting group values</b>	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Number of subjects	6	6	7
Age categorical			
Units: Subjects			
Adults (18-64 years)	6	6	7
Age Continuous			
Units: years			
arithmetic mean	34.7	41.5	47.0
standard deviation	± 12.1	± 11.8	± 6.1
Sex: Female, Male			
Units: Participants			
Female	3	2	4
Male	3	4	3

Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	5	5	7
Native Hawaiian or Other Pacific Islander	1	0	0
Black or African American	0	0	0
White	0	1	0
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	6	6	7
Unknown or Not Reported	0	0	0

Reporting group values	Part 2: POM Cohort 5	Part 3: Cohort A	Part 3: Cohort B
Number of subjects	6	32	10
Age categorical			
Units: Subjects			
Adults (18-64 years)	6	32	10
Age Continuous			
Units: years			
arithmetic mean	40.7	47.2	43.8
standard deviation	± 15.3	± 8.3	± 9.8
Sex: Female, Male			
Units: Participants			
Female	1	13	5
Male	5	19	5
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	5	25	5
Native Hawaiian or Other Pacific Islander	0	1	1
Black or African American	0	0	0
White	1	6	4
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	6	30	9
Unknown or Not Reported	0	2	1

Reporting group values	Part 3: Cohort C	Total	
Number of subjects	30	192	
Age categorical			
Units: Subjects			
Adults (18-64 years)	30	192	

Age Continuous Units: years arithmetic mean standard deviation	32.8 ± 7.7	-	
Sex: Female, Male Units: Participants			
Female	7	40	
Male	23	152	
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	28	102	
Native Hawaiian or Other Pacific Islander	1	10	
Black or African American	0	1	
White	1	76	
More than one race	0	1	
Unknown or Not Reported	0	2	
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	9	
Not Hispanic or Latino	30	180	
Unknown or Not Reported	0	3	

### Subject analysis sets

Subject analysis set title	Part 1
Subject analysis set type	Full analysis

Subject analysis set description:

Healthy volunteers (HVs) received a single dose (Part 1a and Part 1b) or multiple doses (Part 1c) of RO7049389 or placebo under fasted or fed conditions. Participants in Part 1c additionally received two doses of midazolam.

Subject analysis set title	Part 2
Subject analysis set type	Full analysis

Subject analysis set description:

Participants with chronic hepatitis B virus (CHB) infection received RO7049389 or placebo once daily (QD) or twice daily (BID) for 27 days, followed by a single dose on Day 28.

Subject analysis set title	Part 3
Subject analysis set type	Full analysis

Subject analysis set description:

Treatment-naïve or treatment-suppressed participants with CHB were given RO7049389 + NUC (Cohorts A and B) or RO7049389 + NUC + PEG-IFN (Cohort C) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.

Reporting group values	Part 1	Part 2	Part 3
Number of subjects	83	37	72
Age categorical Units: Subjects			
Adults (18-64 years)	83	37	72
Age Continuous Units: years arithmetic mean standard deviation	  ±	  ±	  ±

Sex: Female, Male Units: Participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino Not Hispanic or Latino Unknown or Not Reported			

## End points

### End points reporting groups

Reporting group title	Parts 1a and 1b: Single ascending dose (SAD) Placebo
Reporting group description: Healthy volunteers (HVs) received a single dose of placebo under fasted (Part 1a) or fed (Part 1b) conditions.	
Reporting group title	Part 1c: Multiple ascending dose (MAD) Placebo
Reporting group description: HVs received placebo either once-daily (QD) or twice-daily (BID) for 13 days, followed by a single dose on Day 14.	
Reporting group title	Part 2: Proof-of-Mechanism (POM) Placebo
Reporting group description: Participants with chronic hepatitis B virus (CHB) infection received placebo once daily (QD) or twice daily (BID) for 27 days, followed by a single dose on Day 28.	
Reporting group title	Part 1a: SAD Cohort 1
Reporting group description: HVs received a single dose of 150 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1a and Part 1b: SAD Cohort 2 (food effect)
Reporting group description: Part 1a: HVs received a single dose of 450 mg of RO7049389 under fasted conditions. Part 1b: HVs received a single dose of 450 mg of RO7049389 on Day 16 after a standard US FDA-recommended high-fat high-calorie meal.	
Reporting group title	Part 1a: SAD Cohort 3
Reporting group description: HVs received a single dose of 1000 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1a: SAD Cohort 4
Reporting group description: HVs received a single dose of 2000 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1a: SAD Cohort 5
Reporting group description: HVs received a single dose of 1000 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1a: SAD Cohort 6
Reporting group description: HVs received a single dose of 2500 mg of RO7049389 under fasted conditions.	
Reporting group title	Part 1c: MAD Cohort 1
Reporting group description: HVs received 200 mg of RO7049389 BID under fasted conditions for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Reporting group title	Part 1c: MAD Cohort 2
Reporting group description: HVs received 200 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Reporting group title	Part 1c: MAD Cohort 3
Reporting group description: HVs received 400 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Reporting group title	Part 1c: MAD Cohort 4
Reporting group description: HVs received 800 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	

Reporting group title	Part 1c: MAD Cohort 5
Reporting group description: HVs received 600 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.	
Reporting group title	Part 2: POM Cohort 1
Reporting group description: Participants with CHB received 200 mg of RO7049389 BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.	
Reporting group title	Part 2: POM Cohort 2
Reporting group description: Participants with CHB received 400 mg of RO7049389 BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.	
Reporting group title	Part 2: POM Cohort 3
Reporting group description: Participants with CHB received 600 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Reporting group title	Part 2: POM Cohort 4
Reporting group description: Participants with CHB received 1000 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Reporting group title	Part 2: POM Cohort 5
Reporting group description: Participants with CHB received 200 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.	
Reporting group title	Part 3: Cohort A
Reporting group description: Nucleos(t)ide (NUC)-suppressed CHB participants received 600 mg of RO7049389 QD under fasted conditions in addition to an NUC (administered per local SoC) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.	
Reporting group title	Part 3: Cohort B
Reporting group description: Treatment-naïve immune-active CHB participants 600 mg of RO7049389 QD under fasted conditions for 4 weeks, followed by RO7049389 + NUC (administered per local SoC) for an additional 44 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.	
Reporting group title	Part 3: Cohort C
Reporting group description: Treatment-naïve immune-active CHB participants received 600 mg of RO7049389 QD under fasted conditions + NUC + pegylated interferon (Peg-IFN) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.	
Subject analysis set title	Part 1
Subject analysis set type	Full analysis
Subject analysis set description: Healthy volunteers (HVs) received a single dose (Part 1a and Part 1b) or multiple doses (Part 1c) of RO7049389 or placebo under fasted or fed conditions. Participants in Part 1c additionally received two doses of midazolam.	
Subject analysis set title	Part 2
Subject analysis set type	Full analysis
Subject analysis set description: Participants with chronic hepatitis B virus (CHB) infection received RO7049389 or placebo once daily (QD) or twice daily (BID) for 27 days, followed by a single dose on Day 28.	
Subject analysis set title	Part 3
Subject analysis set type	Full analysis
Subject analysis set description: Treatment-naïve or treatment-suppressed participants with CHB were given RO7049389 + NUC (Cohorts A and B) or RO7049389 + NUC + PEG-IFN (Cohort C) for 48 weeks. After the study treatment period,	

participants either continued NUC for another 24 weeks, or discontinued all treatment.

### Primary: Part 1: Percentage of Participants With Adverse Events

End point title Part 1: Percentage of Participants With Adverse Events<sup>[1][2]</sup>

End point description:

End point type Primary

End point timeframe:

Up to Day 29 (Part 1a), Day 44 (Part 1b), Day 42 (Part 1c)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Parts 1a and 1b: Single ascending dose (SAD) Placebo	Part 1c: Multiple ascending dose (MAD) Placebo	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	10	3	6
Units: Percentage of participants				
number (not applicable)	27.3	60.0	33.3	50.0

End point values	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	6	6
Units: Percentage of participants				
number (not applicable)	100	83.3	33.3	50.0

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	7	6
Units: Percentage of participants				
number (not applicable)	83.3	57.1	28.6	16.7

End point values	Part 1c: MAD Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Percentage of participants				

number (not applicable)	16.7			
-------------------------	------	--	--	--

## Statistical analyses

No statistical analyses for this end point

### Primary: Parts 1a and 1b: SAD Cohort: Time to Reach Maximum Concentration (Tmax) of RO7049389

End point title	Parts 1a and 1b: SAD Cohort: Time to Reach Maximum Concentration (Tmax) of RO7049389 <sup>[3]</sup> <sup>[4]</sup>
End point description:	9999 = No data collected for fed state because cohort was only in fasted state
End point type	Primary
End point timeframe:	Up to 28 days

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	6
Units: Hours				
median (full range (min-max))				
Fasted	2.0 (2.0 to 2.0)	1.25 (1.0 to 2.0)	1.5 (1.5 to 3.0)	2.0 (1.5 to 3.0)
Fed	9999 (9999 to 9999)	3.0 (1.5 to 4.0)	9999 (9999 to 9999)	9999 (9999 to 9999)

End point values	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: Hours				
median (full range (min-max))				
Fasted	1.5 (1.5 to 3.0)	3.0 (1.5 to 4.0)		
Fed	9999 (9999 to 9999)	9999 (9999 to 9999)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Parts 1a and 1b: SAD Cohort: Maximum Observed Plasma Concentration (C<sub>max</sub>) of RO7049389

End point title	Parts 1a and 1b: SAD Cohort: Maximum Observed Plasma Concentration (C <sub>max</sub> ) of RO7049389 <sup>[5][6]</sup>
End point description:	9999 = No data collected for fed state because cohort was only in fasted state
End point type	Primary
End point timeframe:	Up to 28 days

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	250 (± 33.4)	1900 (± 79.7)	8990 (± 77.4)	14700 (± 67.6)
Fed	9999 (± 9999)	4610 (± 75.6)	9999 (± 9999)	9999 (± 9999)

End point values	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	8990 (± 77.4)	24800 (± 63.9)		
Fed	9999 (± 9999)	9999 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Parts 1a and 1b: SAD Cohort: AUC From Time Zero to Infinity (AUC0-inf) of RO7049389

End point title	Parts 1a and 1b: SAD Cohort: AUC From Time Zero to Infinity (AUC0-inf) of RO7049389 <sup>[7]</sup> <sup>[8]</sup>
-----------------	-------------------------------------------------------------------------------------------------------------------

End point description:

9999 = No data collected for fed state because cohort was only in fasted state

End point type	Primary
----------------	---------

End point timeframe:

Up to 28 days

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	879 (± 7.5)	4690 (± 53.2)	34400 (± 71.6)	46300 (± 62.0)
Fed	9999 (± 9999)	10900 (± 71.9)	9999 (± 9999)	9999 (± 9999)

End point values	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	34400 (± 71.6)	134000 (± 91.4)		
Fed	9999 (± 9999)	9999 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Parts 1a and 1b: SAD Cohort: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of RO7049389

End point title	Parts 1a and 1b: SAD Cohort: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of RO7049389 <sup>[9]</sup> <sup>[10]</sup>
End point description: 9999 = No data collected for fed state because cohort was only in fasted state	
End point type	Primary
End point timeframe: Up to 28 days	

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	868 (± 6.6)	4660 (± 53.8)	34300 (± 71.6)	46200 (± 62.1)
Fed	9999 (± 9999)	10900 (± 72.0)	9999 (± 9999)	9999 (± 9999)

End point values	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	34300 (± 71.6)	134000 (± 91.4)		
Fed	9999 (± 9999)	9999 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Primary: Parts 1a and 1b: SAD Cohort: Half-life (T1/2) of RO7049389

End point title	Parts 1a and 1b: SAD Cohort: Half-life (T1/2) of
End point description: 9999 = No data collected for fed state because cohort was only in fasted state	
End point type	Primary

End point timeframe:

Up to Day 28

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	6
Units: Hours				
geometric mean (geometric coefficient of variation)				
Fasted	3.34 (± 35.3)	8.80 (± 81.1)	7.23 (± 39.5)	12.1 (± 52.1)
Fed	9999 (± 9999)	4.20 (± 32.0)	9999 (± 9999)	9999 (± 9999)

End point values	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: Hours				
geometric mean (geometric coefficient of variation)				
Fasted	7.23 (± 39.5)	12.4 (± 44.7)		
Fed	9999 (± 9999)	9999 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Primary: Parts 1a and 1b: SAD Cohort: Apparent Oral Clearance (CL/F) of RO7049389

End point title	Parts 1a and 1b: SAD Cohort: Apparent Oral Clearance (CL/F) of RO7049389 <sup>[13][14]</sup>
-----------------	----------------------------------------------------------------------------------------------

End point description:

9999 = No data collected for fed state because cohort was only in fasted state

End point type	Primary
----------------	---------

End point timeframe:

Up to Day 28

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	171 ( $\pm$ 7.3)	128 ( $\pm$ 67.8)	64.9 ( $\pm$ 130.3)	63.3 ( $\pm$ 69.7)
Fed	9999 ( $\pm$ 9999)	61.5 ( $\pm$ 72.1)	9999 ( $\pm$ 9999)	9999 ( $\pm$ 9999)

End point values	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	64.9 ( $\pm$ 130.3)	69.7 ( $\pm$ 122.3)		
Fed	9999 ( $\pm$ 9999)	9999 ( $\pm$ 9999)		

## Statistical analyses

No statistical analyses for this end point

## Primary: Parts 1a and 1b: SAD Cohort: Cumulative Amount Excreted Unchanged in Urine (Ae) of RO7049389

End point title	Parts 1a and 1b: SAD Cohort: Cumulative Amount Excreted Unchanged in Urine (Ae) of RO7049389 <sup>[15]</sup> <sup>[16]</sup>
-----------------	------------------------------------------------------------------------------------------------------------------------------

End point description:

999 = Data unavailable because this parameter was not measured for this cohort.

9999 = No data collected for fed state because cohort was only in fasted state

End point type	Primary
----------------	---------

End point timeframe:

Up to Day 28

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	999 (± 999)	0.312 (± 69.6)	1.88 (± 83.9)	3.56 (± 92.0)
Fed	9999 (± 9999)	999 (± 999)	9999 (± 9999)	9999 (± 9999)

End point values	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	1.88 (± 83.9)	6.89 (± 101.8)		
Fed	9999 (± 9999)	9999 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Primary: Parts 1a and 1b: SAD Cohort: Renal Clearance (CLr) of RO7049389

End point title	Parts 1a and 1b: SAD Cohort: Renal Clearance (CLr) of RO7049389 <sup>[17]</sup> <sup>[18]</sup>
-----------------	-------------------------------------------------------------------------------------------------

End point description:

999 = Data unavailable because this parameter was not measured for this cohort.

9999 = No data collected for fed state because cohort was only in fasted state

End point type	Primary
----------------	---------

End point timeframe:

Up to Day 28

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1a: SAD Cohort 1	Part 1a and Part 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	999 (± 999)	1.60 (± 84.8)	1.55 (± 42.9)	1.41 (± 18.7)
Fed	9999 (± 9999)	999 (± 999)	9999 (± 9999)	9999 (± 9999)

End point values	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Fasted	1.55 (± 42.9)	0.82 (± 22.8)		
Fed	9999 (± 9999)	9999 (± 9999)		

## Statistical analyses

No statistical analyses for this end point

## Primary: Part 2: Percentage of Participants With Adverse Events

End point title	Part 2: Percentage of Participants With Adverse Events <sup>[19][20]</sup>
-----------------	----------------------------------------------------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Up to Day 112

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: Proof-of-Mechanism (POM) Placebo	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: Percentage of participants				
number (not applicable)	50.0	66.7	66.7	83.3

End point values	Part 2: POM Cohort 4	Part 2: POM Cohort 5		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	6		
Units: Percentage of participants				
number (not applicable)	57.1	33.3		

## Statistical analyses

No statistical analyses for this end point

## Primary: Part 2: Quantitative Plasma HBV DNA Level

End point title	Part 2: Quantitative Plasma HBV DNA Level <sup>[21]</sup> <sup>[22]</sup>
-----------------	---------------------------------------------------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Baseline - Day 112

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: Proof-of-Mechanism (POM) Placebo	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6 <sup>[23]</sup>	6 <sup>[24]</sup>	6 <sup>[25]</sup>	6
Units: Log10 IU/mL				
median (full range (min-max))				
Baseline	5.94 (4.8 to 8.2)	4.50 (1.9 to 8.3)	7.80 (4.0 to 8.5)	4.43 (3.3 to 8.4)
Day 8	5.25 (4.6 to 7.8)	1.40 (1.3 to 4.8)	5.27 (1.8 to 6.2)	1.75 (1.3 to 5.7)
Day 15	5.29 (4.3 to 8.1)	2.00 (1.3 to 5.4)	4.58 (1.4 to 6.0)	1.46 (1.3 to 5.5)
Day 22	5.16 (3.8 to 8.0)	1.83 (1.3 to 5.1)	4.11 (1.3 to 5.8)	1.41 (1.3 to 5.2)
Day 28	5.29 (3.6 to 8.0)	1.65 (1.3 to 4.9)	3.64 (1.3 to 5.8)	1.30 (1.3 to 4.9)
Day 35/Follow-up Day 7	5.29 (2.7 to 8.0)	3.23 (1.3 to 8.0)	5.50 (2.8 to 6.6)	2.61 (1.5 to 6.9)
Day 56/Follow-up Day 28	5.21 (2.7 to 8.1)	4.07 (2.4 to 8.3)	6.53 (3.3 to 8.2)	3.43 (2.8 to 9.1)
Day 84/Follow-up Day 56	5.15 (2.6 to 8.2)	5.76 (2.4 to 8.0)	5.68 (4.4 to 8.1)	4.29 (3.5 to 8.2)

Day 112/Follow-up Day 84	5.09 (3.0 to 8.0)	5.89 (3.2 to 7.9)	6.17 (4.1 to 8.2)	4.45 (3.2 to 8.4)
--------------------------	-------------------	-------------------	-------------------	-------------------

Notes:

[23] - Days 8-112 n=5

[24] - Day 8 n=5

Days 84,112 n=4

[25] - Day 84 n=5

End point values	Part 2: POM Cohort 4	Part 2: POM Cohort 5		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7 <sup>[26]</sup>	6		
Units: Log10 IU/mL				
median (full range (min-max))				
Baseline	5.10 (4.1 to 8.7)	7.14 (3.9 to 8.5)		
Day 8	2.25 (1.3 to 6.5)	5.21 (2.0 to 6.0)		
Day 15	1.30 (1.3 to 6.0)	4.90 (1.3 to 5.6)		
Day 22	1.41 (1.3 to 5.6)	4.65 (1.3 to 5.4)		
Day 28	1.30 (1.3 to 5.5)	4.43 (1.3 to 5.4)		
Day 35/Follow-up Day 7	2.98 (2.4 to 6.7)	6.29 (2.4 to 7.6)		
Day 56/Follow-up Day 28	4.04 (3.1 to 8.3)	7.07 (3.9 to 8.3)		
Day 84/Follow-up Day 56	4.73 (3.7 to 8.5)	6.83 (3.8 to 8.4)		
Day 112/Follow-up Day 84	4.55 (4.0 to 8.4)	7.03 (3.8 to 8.3)		

Notes:

[26] - Days 8-22, 56-112 n=6

Days 28, 35 n=5

## Statistical analyses

No statistical analyses for this end point

## Primary: Part 3: Proportion of patients achieving functional cure

End point title	Part 3: Proportion of patients achieving functional cure <sup>[27][28]</sup>
-----------------	------------------------------------------------------------------------------

End point description:

Functional cure is defined as HBV DNA < lower limit of quantification (LLOQ, 20 IU/mL) with HBsAg loss (< 0.05 IU/mL) at 24 weeks post-treatment.

End point type	Primary
----------------	---------

End point timeframe:

Every 2-4 weeks from Baseline through Week 72

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical summaries for each endpoint are descriptive with no planned formal analyses.

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	10	30	
Units: Percentage				
number (confidence interval 95%)				
Baseline	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 2	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 4	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 8	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 12	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 16	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 20	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 24	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 28	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 32	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 36	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 40	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 44	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 48	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 50	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 52	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 54	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 56	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 58	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 60	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 64	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 68	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	
Week 72	0 (0 to 0.11)	0 (0 to 0.31)	0 (0 to 0.12)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1b: Food effect on Cmax of RO7049389

End point title	Part 1b: Food effect on Cmax of RO7049389 <sup>[29]</sup>
End point description: This endpoint presents the geometric mean ratio (fed/fasted).	
End point type	Secondary
End point timeframe: Day 16	

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

<b>End point values</b>	Part 1a and Part 1b: SAD Cohort 2 (food effect)			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: ng/mL				
geometric mean (confidence interval 90%)	2.42 (1.48 to 3.95)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1b: Food effect on AUCinf of RO7049389

End point title	Part 1b: Food effect on AUCinf of RO7049389 <sup>[30]</sup>
End point description: This endpoint presents the geometric mean ratio (fed/fasted).	
End point type	Secondary
End point timeframe: Day 16	

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

<b>End point values</b>	Part 1a and Part 1b: SAD Cohort 2 (food effect)			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: h*ng/mL				
geometric mean (confidence interval 90%)	2.17 (1.39 to 3.40)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1c: Cmax of Midazolam

End point title	Part 1c: Cmax of Midazolam <sup>[31]</sup>
End point description: This endpoint presents the geometric mean ratio (after RO7049389/before RO7049389).	
End point type	Secondary
End point timeframe: Up to Day 14	

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 5
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: pg/mL				
geometric mean (confidence interval 90%)	0.892 (0.663 to 1.20)	1.01 (0.846 to 1.21)	1.12 (0.915 to 1.37)	0.940 (0.734 to 1.21)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1c: AUCinf of Midazolam

End point title	Part 1c: AUCinf of Midazolam <sup>[32]</sup>
End point description: This endpoint presents the geometric mean ratio (after RO7049389/before RO7049389).	
End point type	Secondary
End point timeframe: Up to Day 14	

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 5
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: hr*pg/mL				
geometric mean (confidence interval 90%)	1.10 (0.846 to 1.42)	1.18 (1.06 to 1.31)	1.25 (1.04 to 1.50)	1.16 (0.993 to 1.36)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1c: Tmax of RO7049389

End point title	Part 1c: Tmax of RO7049389 <sup>[33]</sup>
End point description:	
End point type	Secondary

End point timeframe:

Up to Day 14

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7 <sup>[34]</sup>	7 <sup>[35]</sup>	6 <sup>[36]</sup>
Units: hours				
median (full range (min-max))				
Day 1	2.0 (1.5 to 3.0)	2.0 (1.5 to 3.0)	3.0 (1.5 to 4.0)	3.0 (3.0 to 4.0)
Day 14	1.5 (1.0 to 1.5)	2.0 (1.5 to 4.0)	3.0 (1.5 to 4.0)	9999 (9999 to 9999)

Notes:

[34] - Day 14 n = 6

[35] - Day 14 n = 6

[36] - 9999 = No data collected for Day 14

End point values	Part 1c: MAD Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: hours				
median (full range (min-max))				
Day 1	3.0 (2.0 to 3.0)			
Day 14	3.0 (3.0 to 4.0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1c: Cmax of R07049389

End point title | Part 1c: Cmax of R07049389<sup>[37]</sup>

End point description:

End point type | Secondary

End point timeframe:

Up to Day 14

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7 <sup>[38]</sup>	7 <sup>[39]</sup>	6 <sup>[40]</sup>
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Day 1	483 (± 42.5)	840 (± 41.7)	4840 (± 53.7)	14500 (± 39.5)
Day 14	735 (± 19.9)	583 (± 41.3)	2720 (± 49.0)	9999 (± 9999)

Notes:

[38] - Day 14 n = 6

[39] - Day 14 n = 6

[40] - 9999 = No data collected for Day 14

End point values	Part 1c: MAD Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Day 1	10600 (± 42.2)			
Day 14	9960 (± 32.7)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1c: AUC0-12hr of RO7049389

End point title	Part 1c: AUC0-12hr of RO7049389 <sup>[41]</sup>
-----------------	-------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 14

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7 <sup>[42]</sup>	7 <sup>[43]</sup>	6 <sup>[44]</sup>
Units: ng*hr/mL				
geometric mean (geometric coefficient of variation)				
Day 1	1304.09 (± 31.9)	1819.92 (± 46.1)	9760.31 (± 55.7)	32459.87 (± 42.6)
Day 14	1806.59 (± 25.6)	1573.32 (± 27.5)	6511.21 (± 29.0)	9999 (± 9999)

Notes:

[42] - Day 14 n = 6

[43] - Day 14 n = 6

[44] - 9999 = No data collected for Day 14

<b>End point values</b>	Part 1c: MAD Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: ng*hr/mL				
geometric mean (geometric coefficient of variation)				
Day 1	27041.94 ( $\pm$ 33.6)			
Day 14	28051.71 ( $\pm$ 32.5)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1c: CLr of R07049389

End point title	Part 1c: CLr of R07049389 <sup>[45]</sup>
-----------------	-------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 14

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

<b>End point values</b>	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7 <sup>[46]</sup>	7 <sup>[47]</sup>	6 <sup>[48]</sup>
Units: mL/min				
geometric mean (geometric coefficient of variation)				
Day 1	1.06 ( $\pm$ 74.2)	1.08 ( $\pm$ 82.6)	1.43 ( $\pm$ 27.0)	2.04 ( $\pm$ 54.7)
Day 14	1.96 ( $\pm$ 75.2)	1.87 ( $\pm$ 51.7)	3.01 ( $\pm$ 46.9)	9999 ( $\pm$ 9999)

Notes:

[46] - Day 14 n = 6

[47] - Day 14 n = 6

[48] - 9999 = No data collected for Day 14

<b>End point values</b>	Part 1c: MAD Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			

Units: mL/min				
geometric mean (geometric coefficient of variation)				
Day 1	1.19 (± 48.6)			
Day 14	2.32 (± 35.0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1c: Accumulation Ratio of R07049389

End point title	Part 1c: Accumulation Ratio of R07049389 <sup>[49]</sup>
-----------------	----------------------------------------------------------

End point description:

This endpoint presents the geometric mean ratio (fed/fasted).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 14

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 5
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	7	6
Units: None				
geometric mean (geometric coefficient of variation)	1.45 (± 24.3)	1.05 (± 31.1)	0.880 (± 35.6)	1.09 (± 37.4)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1c: T1/2 of R07049389

End point title	Part 1c: T1/2 of R07049389 <sup>[50]</sup>
-----------------	--------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 14

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7 <sup>[51]</sup>	7 <sup>[52]</sup>	6 <sup>[53]</sup>
Units: Hours				
geometric mean (geometric coefficient of variation)				
Day 1	2.27 (± 24.1)	2.44 (± 12.6)	2.09 (± 18.5)	1.70 (± 30.4)
Day 14	5.79 (± 40.7)	5.17 (± 26.8)	5.08 (± 10.5)	9999 (± 9999)

Notes:

[51] - Day 14 n = 6

[52] - Day 14 n = 6

[53] - 9999 = No data collected for Day 14

End point values	Part 1c: MAD Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Hours				
geometric mean (geometric coefficient of variation)				
Day 1	1.53 (± 22.5)			
Day 14	5.73 (± 28.9)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1c: Ae of RO7049389

End point title	Part 1c: Ae of RO7049389 <sup>[54]</sup>
-----------------	------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 14

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7 <sup>[55]</sup>	7 <sup>[56]</sup>	6 <sup>[57]</sup>
Units: mg				
geometric mean (geometric coefficient of variation)				
Day 1	0.0926 (± 90.7)	0.0900 (± 56.0)	0.859 (± 60.9)	3.58 (± 63.4)
Day 14	0.243 (± 89.5)	0.189 (± 60.7)	1.26 (± 53.8)	9999 (± 9999)

Notes:

[55] - Day 14 n = 6

[56] - Day 14 n = 6

[57] - 9999 = No data collected for Day 14

<b>End point values</b>	Part 1c: MAD Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: mg				
geometric mean (geometric coefficient of variation)				
Day 1	1.77 (± 35.9)			
Day 14	3.68 (± 26.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1c: Ctrough of R07049389

End point title	Part 1c: Ctrough of R07049389 <sup>[58]</sup>
-----------------	-----------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Day 14

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

<b>End point values</b>	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3	Part 1c: MAD Cohort 5
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7 <sup>[59]</sup>	7 <sup>[60]</sup>	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)	12.1 (± 45.1)	15.2 (± 27.8)	42.1 (± 12.8)	88.9 (± 27.6)

Notes:

[59] - Day 14 n = 6

[60] - Day 14 n = 6

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 2: HBV DNA < Lower Limit of Quantification (LLOQ)

End point title	Part 2: HBV DNA < Lower Limit of Quantification (LLOQ) <sup>[61]</sup>
-----------------	------------------------------------------------------------------------

End point description:

End point type	Secondary
End point timeframe:	
Baseline - Day 112/Follow-up Day 84	

Notes:

[61] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: Proof-of-Mechanism (POM) Placebo	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6 <sup>[62]</sup>	6 <sup>[63]</sup>	6 <sup>[64]</sup>	6
Units: Percentage of participants				
number (not applicable)				
Baseline	0	0	0	0
Day 8	0	0	33.3	0
Day 15	16.7	0	50.0	0
Day 22	16.7	0	50.0	0
Day 28	16.7	0	50.0	16.7
Day 35/Follow-up Day 7	0	0	16.7	0
Day 56/Follow-up Day 28	0	0	0	0
Day 84/Follow-up Day 56	0	0	0	0
Day 112/Follow-up Day 84	0	0	0	0

Notes:

[62] - Days 8-112 n=5

[63] - Day 8 n=5

Days 84, 112 n=4

[64] - Day 84 n=5

End point values	Part 2: POM Cohort 4	Part 2: POM Cohort 5		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7 <sup>[65]</sup>	6		
Units: Percentage of participants				
number (not applicable)				
Baseline	0	0		
Day 8	50.0	28.6		
Day 15	50.0	57.1		
Day 22	50.0	42.9		
Day 28	66.7	57.1		
Day 35/Follow-up Day 7	0	0		
Day 56/Follow-up Day 28	0	0		
Day 84/Follow-up Day 56	0	0		
Day 112/Follow-up Day 84	0	0		

Notes:

[65] - Days 8-112 n=6

## Statistical analyses

No statistical analyses for this end point

**Secondary: Part 2: Tmax of R07049389**End point title Part 2: Tmax of R07049389<sup>[66]</sup>

End point description:

End point type Secondary

End point timeframe:

Up to Day 28

Notes:

[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: Hours				
median (full range (min-max))				
Day 1	2.0 (2.0 to 3.0)	3.0 (2.0 to 3.0)	1.97 (0.92 to 3.0)	1.98 (1.92 to 3.03)
Day 28	2.5 (1.08 to 3.0)	2.5 (2.0 to 4.0)	2.0 (0.97 to 3.0)	2.03 (1.90 to 2.85)

End point values	Part 2: POM Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Hours				
median (full range (min-max))				
Day 1	1.5 (1.0 to 2.87)			
Day 28	1.5 (0.833 to 3.0)			

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Part 2: Cmax of R07049389**End point title Part 2: Cmax of R07049389<sup>[67]</sup>

End point description:

End point type Secondary

End point timeframe:

Up to Day 28

Notes:

[67] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Day 1	1450 (± 69.1)	8110 (± 59.7)	5030 (± 42.7)	23900 (± 41.8)
Day 28	1500 (± 60.3)	8580 (± 63.7)	4890 (± 76.9)	29800 (± 15.2)

End point values	Part 2: POM Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Day 1	910 (± 89.1)			
Day 28	998 (± 52.8)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 2: AUCtau of RO7049389

End point title	Part 2: AUCtau of RO7049389 <sup>[68]</sup>
-----------------	---------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 28

Notes:

[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: ng*hr/mL				
geometric mean (geometric coefficient of variation)				
Day 1	2870 (± 50.2)	19900 (± 78.6)	11500 (± 65.5)	80000 (± 71.2)
Day 28	3350 (± 47.7)	22400 (± 70.5)	14600 (± 78.0)	133000 (± 50.0)

End point values	Part 2: POM Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: ng*hr/mL				
geometric mean (geometric coefficient of variation)				
Day 1	3500 (± 76.7)			
Day 28	3480 (± 56.9)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 2: Accumulation Ratio of RO7049389

End point title	Part 2: Accumulation Ratio of RO7049389 <sup>[69]</sup>
End point description:	This endpoint presents the geometric mean ratio (fed/fasted).
End point type	Secondary
End point timeframe:	Up to Day 28

Notes:

[69] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: None				
geometric mean (geometric coefficient of variation)	1.01 (± 81.3)	0.971 (± 58.2)	1.65 (± 109.8)	0.823 (± 77.0)

End point values	Part 2: POM			
------------------	-------------	--	--	--

	Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: None				
geometric mean (geometric coefficient of variation)	0.917 ( $\pm$ 40.9)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 2: T1/2 of RO7049389

End point title	Part 2: T1/2 of RO7049389 <sup>[70]</sup>
-----------------	-------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 28

Notes:

[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: Hours				
geometric mean (geometric coefficient of variation)				
Day 1	1.68 ( $\pm$ 18.0)	1.15 ( $\pm$ 27.6)	1.09 ( $\pm$ 22.4)	1.40 ( $\pm$ 34.5)
Day 28	3.38 ( $\pm$ 24.1)	3.26 ( $\pm$ 28.8)	3.70 ( $\pm$ 26.1)	2.33 ( $\pm$ 20.1)

End point values	Part 2: POM Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Hours				
geometric mean (geometric coefficient of variation)				
Day 1	2.33 ( $\pm$ 55.2)			
Day 28	3.81 ( $\pm$ 24.6)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 2: Ctrough of R07049389

End point title Part 2: Ctrough of R07049389<sup>[71]</sup>

End point description:

End point type Secondary

End point timeframe:

Day 28

Notes:

[71] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 2: POM Cohort 1	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)	26.7 (± 72.7)	68.2 (± 89.2)	7.94 (± 60.6)	27.0 (± 42.3)

End point values	Part 2: POM Cohort 5			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: ng/mL				
geometric mean (geometric coefficient of variation)	3.37 (± 88.1)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Part 3: Percentage of Participants with AEs

End point title Part 3: Percentage of Participants with AEs<sup>[72]</sup>

End point description:

End point type Secondary

End point timeframe:

72 weeks

Notes:

[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	10	30	
Units: Percentage of participants				
number (not applicable)	68.8	90	100	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 3: Hepatitis B Surface Antigen (HBsAg) Level

End point title Part 3: Hepatitis B Surface Antigen (HBsAg) Level<sup>[73]</sup>

End point description:

End point type Secondary

End point timeframe:

Baseline - Week 72

Notes:

[73] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[74]</sup>	10 <sup>[75]</sup>	30 <sup>[76]</sup>	
Units: Log10 IU/mL				
median (full range (min-max))				
Baseline	3.04 (2.48 to 4.30)	3.51 (2.44 to 4.63)	4.10 (2.50 to 5.49)	
Week 2	3.08 (2.42 to 4.36)	3.51 (2.53 to 4.69)	4.14 (2.18 to 5.63)	
Week 4	3.08 (2.52 to 4.33)	3.47 (2.36 to 4.46)	3.98 (1.74 to 5.55)	
Week 8	3.00 (2.41 to 4.33)	3.49 (2.30 to 4.25)	3.62 (1.34 to 5.06)	
Week 12	3.02 (2.42 to 4.31)	3.52 (2.51 to 4.25)	3.55 (1.44 to 4.82)	
Week 16	3.03 (2.59 to 4.28)	3.22 (2.64 to 4.25)	3.44 (1.56 to 4.46)	
Week 20	3.05 (2.54 to 4.30)	3.48 (2.79 to 4.26)	3.26 (1.47 to 4.37)	
Week 24	2.99 (2.58 to 4.25)	3.84 (2.85 to 4.23)	3.15 (0.98 to 4.30)	
Week 28	3.04 (2.58 to 4.27)	3.39 (2.81 to 4.29)	3.10 (1.04 to 4.33)	
Week 32	2.99 (2.54 to 4.28)	3.52 (3.12 to 4.32)	3.09 (0.82 to 4.27)	
Week 36	2.98 (2.47 to 4.32)	3.50 (2.85 to 4.20)	2.93 (0.83 to 4.21)	
Week 40	3.03 (2.52 to 4.26)	3.81 (2.80 to 4.21)	2.91 (0.80 to 4.24)	

Week 44	3.00 (2.50 to 4.23)	3.81 (2.84 to 4.24)	2.91 (0.38 to 4.20)	
Week 48	2.99 (2.50 to 4.23)	3.53 (2.81 to 4.18)	2.90 (0.05 to 4.15)	
Week 50	2.96 (2.55 to 4.21)	3.21 (3.18 to 3.24)	0.83 (0.21 to 1.72)	
Week 52	2.89 (2.55 to 4.24)	3.21 (3.20 to 3.23)	1.32 (0.37 to 1.78)	
Week 54	2.98 (2.53 to 4.29)	3.51 (3.16 to 3.89)	1.41 (0.36 to 2.02)	
Week 56	2.97 (2.48 to 4.21)	3.75 (2.82 to 4.20)	2.86 (0.45 to 4.25)	
Week 58	2.67 (2.52 to 4.23)	3.15 (3.15 to 3.15)	1.70 (0.48 to 2.19)	
Week 60	3.84 (2.52 to 4.22)	3.20 (3.16 to 3.23)	1.79 (0.50 to 2.25)	
Week 64	2.98 (2.50 to 4.23)	3.53 (2.85 to 4.00)	2.83 (0.76 to 4.85)	
Week 68	2.65 (2.56 to 2.74)	3.12 (3.12 to 3.12)	1.84 (1.00 to 2.46)	
Week 72	2.95 (2.49 to 4.17)	3.71 (2.83 to 4.23)	2.75 (0.78 to 4.30)	

Notes:

[74] - Weeks:

2,4,64,72: n=31

8-48, 56: n=30

50: n=11

52: n=10

54: n=9

58: n=3

60: n=6

68: n=2

[75] - Weeks:

16,24,40,44,56,72: n=9

32,64: n=8

50,52,60: n=2

54: n=4

58,68: n=1

[76] - Weeks:

2,8,16-32: n=29

36-48, 56, 64, 72: n=28

50-54, 58, 60, 68: n=5

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 3: Hepatitis B e-Antigen (HBeAg) Levels

End point title	Part 3: Hepatitis B e-Antigen (HBeAg) Levels <sup>[77]</sup>
-----------------	--------------------------------------------------------------

End point description:

The population for this endpoint included participants in Part 3 that were HBeAg+ at baseline.

9999 = No participants analyzed for that timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline - Week 72

Notes:

[77] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11 <sup>[78]</sup>	6 <sup>[79]</sup>	19 <sup>[80]</sup>	
Units: Log10 IU/mL				
median (full range (min-max))				
Baseline	0.17 (-0.54 to 1.93)	1.07 (0.00 to 2.44)	2.84 (1.48 to 3.49)	
Week 2	0.16 (-0.54 to 2.31)	1.01 (-0.89 to 2.31)	2.79 (1.16 to 3.55)	
Week 4	0.17 (-0.54 to 2.01)	0.60 (-0.89 to 1.96)	2.57 (0.65 to 3.36)	
Week 8	0.15 (-0.54 to 1.78)	0.33 (-0.89 to 1.19)	2.24 (0.24 to 2.80)	
Week 12	0.12 (-0.54 to 1.74)	0.17 (-0.89 to 0.57)	2.02 (0.20 to 2.55)	
Week 16	0.12 (-0.54 to 1.71)	-0.04 (-0.89 to 0.39)	1.81 (-0.24 to 2.36)	
Week 20	0.06 (-0.54 to 1.55)	-0.12 (-0.89 to 0.37)	1.40 (-0.89 to 2.25)	
Week 24	0.10 (-0.54 to 1.38)	-0.24 (-0.89 to 0.38)	1.31 (-0.89 to 2.10)	
Week 28	0.12 (-0.54 to 1.39)	-0.32 (-0.89 to 0.28)	1.32 (-0.89 to 2.03)	
Week 32	0.14 (-0.54 to 1.14)	-0.40 (-0.89 to 0.38)	1.12 (-0.89 to 1.97)	
Week 36	0.15 (-0.54 to 1.21)	-0.43 (-0.89 to 0.29)	0.96 (-0.89 to 1.89)	
Week 40	0.13 (-0.54 to 1.16)	-0.49 (-0.89 to 0.21)	0.83 (-0.89 to 1.82)	
Week 44	0.16 (-0.54 to 1.14)	-0.50 (-0.89 to 0.34)	0.82 (-0.89 to 1.75)	
Week 48	0.15 (-0.54 to 1.16)	-0.52 (-0.89 to 0.20)	0.69 (-0.89 to 1.79)	
Week 50	-0.53 (-0.54 to -0.52)	-0.71 (-0.89 to -0.54)	-0.47 (-0.47 to -0.47)	
Week 52	-0.54 (-0.54 to -0.54)	-0.71 (-0.89 to -0.54)	-0.54 (-0.54 to -0.54)	
Week 54	-0.54 (-0.54 to -0.54)	-0.54 (-0.54 to -0.54)	-0.49 (-0.49 to -0.49)	
Week 56	0.09 (-0.54 to 1.22)	-0.54 (-0.89 to 0.22)	0.74 (-0.89 to 2.08)	
Week 58	9999 (9999 to 9999)	-0.54 (-0.54 to -0.54)	1.23 (1.23 to 1.23)	
Week 60	9999 (9999 to 9999)	-0.54 (-0.54 to -0.54)	1.70 (1.70 to 1.70)	
Week 64	0.14 (-0.54 to 1.21)	-0.54 (-0.89 to -0.30)	0.36 (-0.89 to 2.96)	
Week 68	9999 (9999 to 9999)	-0.54 (-0.54 to -0.54)	-0.54 (-0.54 to -0.54)	
Week 72	0.08 (-0.54 to 1.16)	-0.35 (-0.89 to 0.36)	-0.23 (-0.89 to 1.96)	

Notes:

[78] - Weeks:

50, 52: n=2

54: n=1

58,60,68: n=0

[79] - Weeks:

40, 72: n=5

50-54: n=2

58, 60, 68: n=1

64: n=4

[80] - Weeks:

16-48, 56, 64, 72: n=18

50-54, 58, 60, 68: n=1

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 3: HBV RNA level

End point title	Part 3: HBV RNA level <sup>[81]</sup>
-----------------	---------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline - Week 72

Notes:

[81] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[82]</sup>	10 <sup>[83]</sup>	30 <sup>[84]</sup>	
Units: Log10 copies/mL				
median (full range (min-max))				
Baseline	0.99 (0.69 to 4.45)	4.02 (0.69 to 6.24)	5.30 (0.69 to 7.50)	
Week 2	0.69 (0.69 to 1.79)	1.04 (0.69 to 3.93)	2.37 (0.69 to 4.53)	
Week 4	0.69 (0.69 to 1.35)	0.84 (0.69 to 2.90)	1.93 (0.69 to 4.97)	
Week 8	0.69 (0.69 to 2.45)	0.69 (0.69 to 1.68)	1.54 (0.69 to 7.03)	
Week 12	0.69 (0.69 to 2.64)	0.69 (0.69 to 0.99)	0.99 (0.69 to 3.37)	
Week 16	0.69 (0.69 to 1.65)	0.69 (0.69 to 0.99)	0.99 (0.69 to 3.08)	
Week 20	0.69 (0.69 to 0.99)	0.69 (0.69 to 0.99)	0.99 (0.69 to 3.24)	
Week 24	0.69 (0.69 to 0.99)	0.69 (0.69 to 0.99)	0.99 (0.69 to 3.09)	
Week 28	0.69 (0.69 to 0.99)	0.69 (0.69 to 0.99)	0.99 (0.69 to 3.03)	
Week 32	0.69 (0.69 to 0.99)	0.69 (0.69 to 0.99)	0.99 (0.69 to 2.87)	
Week 36	0.69 (0.69 to 1.22)	0.69 (0.69 to 0.69)	0.99 (0.69 to 2.92)	
Week 40	0.69 (0.69 to 1.89)	0.69 (0.69 to 0.69)	0.99 (0.69 to 2.65)	
Week 44	0.69 (0.69 to 0.99)	0.69 (0.69 to 0.99)	0.99 (0.69 to 2.73)	
Week 48	0.69 (0.69 to 1.83)	0.69 (0.69 to 0.69)	0.99 (0.69 to 2.70)	

Week 50	0.69 (0.69 to 1.48)	1.02 (0.69 to 1.34)	0.99 (0.69 to 0.99)
Week 52	0.69 (0.69 to 1.75)	1.46 (1.04 to 1.88)	0.99 (0.69 to 0.99)
Week 54	0.69 (0.69 to 1.64)	2.08 (0.69 to 2.76)	0.99 (0.69 to 0.99)
Week 56	0.99 (0.69 to 4.07)	1.94 (0.69 to 3.44)	1.54 (0.69 to 6.09)
Week 58	0.69 (0.69 to 1.44)	1.75 (1.75 to 1.75)	0.99 (0.69 to 2.49)
Week 60	0.69 (0.69 to 1.89)	1.25 (0.69 to 1.82)	0.99 (0.69 to 2.65)
Week 64	0.99 (0.69 to 3.85)	1.28 (0.69 to 2.82)	0.99 (0.69 to 5.98)
Week 68	1.28 (0.99 to 1.56)	1.99 (1.99 to 1.99)	0.99 (0.99 to 1.10)
Week 72	0.99 (0.69 to 3.87)	1.77 (0.69 to 4.52)	1.08 (0.69 to 6.04)

Notes:

[82] - Week

2,4,72:n=31

8,16,24,28,44,48,56:n=30

12,20,32,36:n=29

50: n=11

52: n=10

54,58,60,68: n<10

[83] - Weeks:

16,24,40,44,56,72: n=9

32,64: n=8

50,52,60: n=2

54: n=4

58,68: n=1

[84] - Weeks:

2,8-24,32: n=29

28, 36-48,56,64,71: n=28

50-54,58,60,68: n=5

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 3: HBV Core-Related Antigen (HBcrAg) Levels

End point title	Part 3: HBV Core-Related Antigen (HBcrAg) Levels <sup>[85]</sup>
-----------------	------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline - Week 72

Notes:

[85] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[86]</sup>	10 <sup>[87]</sup>	30 <sup>[88]</sup>	
Units: Log10 U/mL				
median (full range (min-max))				
Baseline	4.10 (1.90 to 6.90)	6.15 (2.90 to 7.80)	7.95 (1.90 to 9.10)	
Week 2	4.10 (1.90 to 6.80)	5.95 (1.90 to 7.60)	7.80 (1.90 to 9.00)	
Week 4	4.20 (1.90 to 6.80)	5.55 (1.90 to 7.20)	7.00 (1.90 to 8.70)	
Week 8	4.30 (1.90 to 6.80)	5.25 (1.90 to 6.50)	6.70 (1.90 to 8.90)	
Week 12	4.30 (1.90 to 6.70)	5.15 (1.90 to 6.20)	6.30 (1.90 to 8.80)	
Week 16	4.05 (1.90 to 6.60)	5.50 (2.90 to 6.00)	6.20 (2.50 to 8.70)	
Week 20	4.10 (2.50 to 6.70)	5.00 (2.90 to 6.00)	5.90 (2.50 to 8.30)	
Week 24	4.20 (2.90 to 6.60)	5.10 (2.50 to 5.90)	5.70 (1.90 to 8.00)	
Week 28	4.05 (2.50 to 6.40)	5.00 (1.90 to 5.90)	5.60 (2.50 to 7.70)	
Week 32	4.20 (2.50 to 6.50)	4.85 (2.90 to 6.10)	5.40 (1.90 to 9.10)	
Week 36	4.05 (2.90 to 6.40)	5.10 (2.90 to 6.10)	5.45 (1.90 to 7.80)	
Week 40	4.10 (2.90 to 6.50)	4.90 (2.50 to 6.10)	5.45 (2.50 to 7.50)	
Week 44	4.35 (2.90 to 6.40)	4.80 (2.50 to 6.10)	5.35 (1.90 to 7.80)	
Week 48	4.10 (2.50 to 6.60)	5.10 (2.90 to 6.00)	5.45 (2.50 to 9.10)	
Week 50	4.00 (1.90 to 4.80)	5.05 (4.80 to 5.30)	3.10 (2.90 to 4.80)	
Week 52	3.60 (1.90 to 4.90)	5.05 (4.90 to 5.20)	3.10 (2.90 to 4.80)	
Week 54	3.30 (2.50 to 4.80)	3.90 (2.50 to 5.50)	3.10 (2.90 to 4.90)	
Week 56	4.15 (2.50 to 6.50)	5.00 (2.90 to 6.10)	5.50 (1.90 to 9.10)	
Week 58	2.50 (2.50 to 4.60)	5.30 (5.30 to 5.30)	3.20 (2.90 to 6.10)	
Week 60	4.15 (2.50 to 4.70)	3.60 (2.50 to 4.70)	2.90 (2.50 to 6.50)	
Week 64	4.20 (2.50 to 6.50)	4.40 (2.90 to 5.60)	5.15 (1.90 to 9.10)	
Week 68	3.80 (2.90 to 4.70)	5.30 (5.30 to 5.40)	3.20 (3.00 to 4.40)	
Week 72	4.20 (1.90 to 6.40)	4.80 (2.50 to 6.50)	4.70 (1.90 to 9.10)	

Notes:

[86] - Weeks:

2,4,72: n=31

8-20,28-48,56: n=30

24: n=29

50: n=11

52: n=10

54,58,60,68: n<10

[87] - Weeks:  
16,24,40,44,56,72: n=9  
32,64: n=8  
50,52,60: n=2  
54: n=4  
58,68: n=1  
[88] - Weeks:  
2,8,16-32: n=29  
36-48,56,65,72: n=28  
50-54,58,60,68: n=5

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 3: Alanine Transaminase (ALT) Normalization in Participants with Baseline ALT Elevation

End point title	Part 3: Alanine Transaminase (ALT) Normalization in Participants with Baseline ALT Elevation <sup>[89]</sup>
-----------------	--------------------------------------------------------------------------------------------------------------

End point description:

This endpoint includes participants from Part 3 with elevated ALT at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 - Week 72

Notes:

[89] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 <sup>[90]</sup>	9	28	
Units: Percentage of participants				
number (not applicable)				
Week 12		66.67	35.71	
Week 24		88.89	62.96	
Week 36		88.89	77.78	
Week 48		88.89	85.19	
Week 56		77.78	81.48	
Week 64		100	92.59	
Week 72		87.5	92.59	

Notes:

[90] - Participants in Cohort A had normal ALT at baseline.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 3: Anti-Hepatitis B Core Antigen (HBc) Antibodies

End point title	Part 3: Anti-Hepatitis B Core Antigen (HBc) Antibodies <sup>[91]</sup>
-----------------	------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 72

Notes:

[91] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	10	30	
Units: Percentage of participants	100	100	100	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 3: HBV DNA level

End point title	Part 3: HBV DNA level <sup>[92]</sup>
-----------------	---------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline - Week 72

Notes:

[92] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[93]</sup>	10 <sup>[94]</sup>	30 <sup>[95]</sup>	
Units: Log10 copies/mL				
median (full range (min-max))				
Baseline	1.28 (1.28 to 1.28)	6.06 (2.61 to 8.84)	7.37 (3.43 to 9.36)	
Week 2	1.28 (1.28 to 1.28)	3.14 (1.28 to 6.47)	3.89 (0.95 to 6.40)	
Week 4	1.28 (1.28 to 1.28)	1.99 (1.28 to 5.44)	2.76 (0.95 to 5.78)	
Week 8	1.28 (1.28 to 1.28)	1.41 (1.28 to 3.73)	1.54 (0.95 to 6.15)	
Week 12	1.28 (1.28 to 1.91)	1.28 (1.28 to 1.97)	1.44 (0.95 to 4.69)	
Week 16	1.28 (1.28 to 1.41)	1.28 (1.28 to 2.33)	1.28 (0.95 to 3.99)	
Week 20	1.28 (1.28 to 1.28)	1.28 (1.28 to 2.01)	1.28 (0.95 to 3.28)	
Week 24	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.45)	1.28 (0.95 to 2.55)	

Week 28	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.28)	1.28 (0.95 to 2.55)
Week 32	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.43)	1.28 (0.95 to 4.11)
Week 36	1.28 (1.28 to 1.32)	1.28 (1.28 to 1.41)	1.28 (0.95 to 2.21)
Week 40	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.62)	1.28 (0.95 to 2.08)
Week 44	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.28)	1.28 (0.95 to 2.39)
Week 48	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.28)	1.28 (0.95 to 2.10)
Week 50	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.28)	0.95 (0.95 to 1.28)
Week 52	1.28 (1.28 to 1.59)	1.28 (1.28 to 1.28)	1.28 (0.95 to 2.01)
Week 54	1.28 (1.28 to 1.30)	1.28 (1.28 to 1.28)	1.28 (0.95 to 2.89)
Week 56	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.53)	1.28 (0.95 to 5.02)
Week 58	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.28)	2.09 (0.95 to 4.88)
Week 60	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.28)	2.52 (0.95 to 5.23)
Week 64	1.28 (1.28 to 1.28)	1.28 (1.28 to 2.94)	1.28 (0.95 to 6.65)
Week 68	1.28 (1.28 to 1.28)	1.28 (1.28 to 1.28)	2.67 (0.95 to 4.66)
Week 72	1.28 (1.28 to 1.28)	1.28 (1.28 to 6.33)	1.28 (0.95 to 4.70)

Notes:

[93] - Weeks:

2,4,64: n=31

8,16-24,32-48,56,72: n=30

12,28: n=29

50: n=11

52: n=10

54,58,60,68: n<10

[94] - Weeks:

16,24,40,44,56,,72: n=9

32: n=8

50,52,60: n=2

54: n=4

58,68: n=1

[95] - Weeks:

2,8,16-28: n=29

32-44,56,64,72: n=28

48: n=27

50--54,58,60,68: n=5

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 3: HBV DNA < Lower Limit of Quantification (LLOQ)

End point title	Part 3: HBV DNA < Lower Limit of Quantification (LLOQ) <sup>[96]</sup>
-----------------	------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline - Week 72

Notes:

[96] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[97]</sup>	10 <sup>[98]</sup>	30 <sup>[99]</sup>	
Units: Percentage of participants				
number (not applicable)				
Baseline	100	0	0	
Week 2	100	10	10.3	
Week 4	100	30	16.7	
Week 8	100	40	41.4	
Week 12	96.4	70	43.3	
Week 16	96.7	77.8	51.7	
Week 20	100	90	55.2	
Week 24	100	88.9	51.7	
Week 28	100	100	55.2	
Week 32	100	87.5	64.3	
Week 36	96.7	90	67.9	
Week 40	100	77.8	71.4	
Week 44	100	100	71.4	
Week 48	100	100	81.5	
Week 50	100	100	100	
Week 52	90	100	80	
Week 54	88.9	100	80	
Week 56	100	88.9	64.3	
Week 58	100	100	40	
Week 60	100	100	20	
Week 64	100	83.3	67.9	
Week 68	100	100	40	
Week 72	100	77.8	78.6	

Notes:

[97] - Weeks:

2,4,64: n=31

8,16-24,32-48,56,72: n=30

12: n=28

28: n=29

50: n=11

52: n=10

54,58,60,68: n<10

[98] - Weeks:

16,24,40,44,56,72: n=9

32: n=8

50,52,60: n=2

54: n=4

58,68: n=1

[99] - Weeks:

2,8,16-28: n=29

32-44,56,64,72: n=28

48: n=27

50-54,58,60,68: n=5

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 3: Tmax of R07049389

End point title Part 3: Tmax of R07049389<sup>[100]</sup>

End point description:

9999 = Data for the endpoint was not collected at the timepoint

End point type Secondary

End point timeframe:

Day 1 - Week 48

Notes:

[100] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[101]</sup>	10 <sup>[102]</sup>	30 <sup>[103]</sup>	
Units: Hours				
median (full range (min-max))				
Day 1	1.99 (0.98 to 3.03)	2.00 (1.00 to 3.02)	1.96 (0.95 to 3.02)	
Week 4	9999 (9999 to 9999)	2.02 (1.00 to 3.02)	9999 (9999 to 9999)	
Week 24	1.94 (0.00 to 3.00)	2.00 (1.00 to 3.00)	2.00 (0.92 to 4.15)	
Week 48	1.02 (0.00 to 3.13)	2.50 (1.00 to 3.05)	2.00 (0.93 to 3.97)	

Notes:

[101] - Weeks 24, 28: n=30

[102] - Weeks 4, 24: n=9

[103] - Week 24: n=29

Week 48: n=28

### Statistical analyses

No statistical analyses for this end point

### Secondary: Part 3: Cmax of R07049389

End point title Part 3: Cmax of R07049389<sup>[104]</sup>

End point description:

9999 = Data for the endpoint was not collected at the timepoint

End point type Secondary

End point timeframe:

Day 1 - Week 48

Notes:

[104] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[105]</sup>	10 <sup>[106]</sup>	30	
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Day 1	7140 (± 107.6)	5390 (± 94.3)	5910 (± 116.8)	
Week 4	9999 (± 9999)	4630 (± 92.8)	9999 (± 9999)	
Week 24	2500 (± 2040.7)	3900 (± 126.9)	4260 (± 89.4)	
Week 48	5410 (± 88.4)	3510 (± 246.1)	3570 (± 133.6)	

Notes:

[105] - Weeks 24, 28: n=30

[106] - Weeks 4, 24: n=9

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 3: AUCtau of RO7049389

End point title	Part 3: AUCtau of RO7049389 <sup>[107]</sup>
End point description:	
9999 = Data for the endpoint was not collected at the timepoint	
End point type	Secondary
End point timeframe:	
Day 1 - Week 48	

Notes:

[107] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[108]</sup>	10 <sup>[109]</sup>	30 <sup>[110]</sup>	
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
Day 1	18700 (± 105.1)	16700 (± 79.3)	20900 (± 107.4)	
Week 4	9999 (± 9999)	13600 (± 117.2)	9999 (± 9999)	
Week 24	15400 (± 121.3)	10500 (± 241.8)	13200 (± 88.2)	
Week 48	14100 (± 84.8)	16000 (± 121.3)	11700 (± 107.6)	

Notes:

[108] - Week 24: n=26

Weeks 48: n=28

[109] - Day 1; Weeks 24, 48: n=8

Week 4: n=9

[110] - Day 1: n=25

Week 24: n=23

Week 48: n=27

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 3: T1/2 of RO7049389

End point title Part 3: T1/2 of RO7049389<sup>[111]</sup>

End point description:

9999 = Data for the endpoint was not collected at the timepoint

End point type Secondary

End point timeframe:

Day 1 - Week 48

Notes:

[111] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is specific to the reported arms.

End point values	Part 3: Cohort A	Part 3: Cohort B	Part 3: Cohort C	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 <sup>[112]</sup>	10 <sup>[113]</sup>	30 <sup>[114]</sup>	
Units: Hours				
median (full range (min-max))				
Day 1	1.16 (0.757 to 1.67)	1.13 (0.891 to 1.31)	1.31 (0.899 to 1.98)	
Week 4	9999 (9999 to 9999)	1.38 (0.897 to 1.89)	9999 (9999 to 9999)	
Week 24	1.30 (0.832 to 2.19)	1.43 (1.17 to 2.38)	1.38 (1.06 to 2.25)	
Week 48	4.05 (2.62 to 7.59)	3.40 (2.63 to 5.85)	3.98 (2.54 to 8.33)	

Notes:

[112] - Week 24: n=26

Week 48: n=27

[113] - Day 1; Weeks 24, 48: n=8

[114] - Day 1: n=25

Week 24: n=23

Week 48: n=27

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to Day 29 (Part 1a), Day 44 (Part 1b), Day 42 (Part 1c), Day 112 (Part 2), and 72 weeks (Part 3)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

### Reporting groups

Reporting group title	Part 3: Cohort B
-----------------------	------------------

Reporting group description:

Treatment-naïve immune-active CHB participants 600 mg of RO7049389 QD under fasted conditions for 4 weeks, followed by RO7049389 + NUC (administered per local SoC) for an additional 44 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.

Reporting group title	Part 3: Cohort A
-----------------------	------------------

Reporting group description:

Nucleos(t)ide (NUC)-suppressed CHB participants received 600 mg of RO7049389 QD under fasted conditions in addition to an NUC (administered per local SoC) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.

Reporting group title	Parts 1a and 1b: Single ascending dose (SAD) Placebo
-----------------------	------------------------------------------------------

Reporting group description:

Healthy volunteers (HVs) received a single dose of placebo under fasted (Part 1a) or fed (Part 1b) conditions.

Reporting group title	Part 3: Cohort C
-----------------------	------------------

Reporting group description:

Treatment-naïve immune-active CHB participants received 600 mg of RO7049389 QD under fasted conditions + NUC + pegylated interferon (Peg-IFN) for 48 weeks. After the study treatment period, participants either continued NUC for another 24 weeks, or discontinued all treatment.

Reporting group title	Part 1a: SAD Cohort 3
-----------------------	-----------------------

Reporting group description:

HVs received a single dose of 1000 mg of RO7049389 under fasted conditions.

Reporting group title	Part 1a: SAD Cohort 4
-----------------------	-----------------------

Reporting group description:

HVs received a single dose of 2000 mg of RO7049389 under fasted conditions.

Reporting group title	Part 1a and 1b: SAD Cohort 2 (food effect)
-----------------------	--------------------------------------------

Reporting group description:

Part 1a: Single oral dose of 450 mg of RO7049389 under fasted conditions.

Part 1b: Single oral dose of 450 mg of RO7049389 on Day 16 after a standard US FDA-recommended high-fat high-calorie meal.

Reporting group title	Part 1a: SAD Cohort 1
-----------------------	-----------------------

Reporting group description:

HVs received a single dose of 150 mg of RO7049389 under fasted conditions.

Reporting group title	Part 2: Proof-of-Mechanism (POM) Placebo
-----------------------	------------------------------------------

Reporting group description:

Participants with chronic hepatitis B virus (CHB) infection received placebo once daily (QD) or twice daily (BID) for 27 days, followed by a single dose on Day 28.

Reporting group title	Part 1c: Multiple ascending dose (MAD) Placebo
-----------------------	------------------------------------------------

Reporting group description:

HVs received placebo either once-daily (QD) or twice-daily (BID) for 13 days, followed by a single dose on Day 14.

Reporting group title	Part 1a: SAD Cohort 5
-----------------------	-----------------------

Reporting group description:

HVs received a single dose of 1000 mg of RO7049389 under fasted conditions.

Reporting group title	Part 1a: SAD Cohort 6
-----------------------	-----------------------

Reporting group description:

HVs received a single dose of 2500 mg of RO7049389 under fasted conditions.

Reporting group title	Part 1c: MAD Cohort 1
-----------------------	-----------------------

Reporting group description:

HVs received 200 mg of RO7049389 BID under fasted conditions for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.

Reporting group title	Part 1c: MAD Cohort 2
-----------------------	-----------------------

Reporting group description:

HVs received 200 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.

Reporting group title	Part 1c: MAD Cohort 3
-----------------------	-----------------------

Reporting group description:

HVs received 400 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.

Reporting group title	Part 1c: MAD Cohort 4
-----------------------	-----------------------

Reporting group description:

HVs received 800 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.

Reporting group title	Part 1c: MAD Cohort 5
-----------------------	-----------------------

Reporting group description:

HVs received 600 mg of RO7049389 BID after a standard US FDA-recommended high-fat high-calorie meal for 13 days, followed by a single dose on Day 14. Participants also received a single oral dose of midazolam on Day -1 and Day 14.

Reporting group title	Part 2: POM Cohort 1
-----------------------	----------------------

Reporting group description:

Participants with CHB received 200 mg of RO7049389 BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.

Reporting group title	Part 2: POM Cohort 2
-----------------------	----------------------

Reporting group description:

Participants with CHB received 400 mg of RO7049389 BID for 27 days after a standard US FDA recommended high-fat high-calorie meal, followed by a single dose on Day 28.

Reporting group title	Part 2: POM Cohort 3
-----------------------	----------------------

Reporting group description:

Participants with CHB received 600 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.

Reporting group title	Part 2: POM Cohort 4
-----------------------	----------------------

Reporting group description:

Participants with CHB received 1000 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.

Reporting group title	Part 2: POM Cohort 5
-----------------------	----------------------

Reporting group description:

Participants with CHB received 200 mg of RO7049389 QD for 27 days under fasted conditions, followed by a single dose on Day 28.

<b>Serious adverse events</b>	Part 3: Cohort B	Part 3: Cohort A	Parts 1a and 1b: Single ascending dose (SAD) Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 10 (10.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
Liver function test increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations Cellulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 10 (10.00%) 0 / 1 0 / 0	0 / 32 (0.00%) 0 / 0 0 / 0	0 / 11 (0.00%) 0 / 0 0 / 0
Upper respiratory tract infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0	0 / 32 (0.00%) 0 / 0 0 / 0	0 / 11 (0.00%) 0 / 0 0 / 0

<b>Serious adverse events</b>	Part 3: Cohort C	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Total subjects affected by serious adverse events subjects affected / exposed number of deaths (all causes) number of deaths resulting from adverse events	2 / 30 (6.67%) 0 0	0 / 3 (0.00%) 0 0	0 / 6 (0.00%) 0 0
Investigations Liver function test increased subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 30 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 30 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Nervous system disorders Dizziness subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 30 (3.33%) 0 / 1 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Blood and lymphatic system disorders Lymphadenitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 30 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Immune system disorders			

Hypersensitivity			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 1a and 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 1	Part 2: Proof-of-Mechanism (POM) Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
Liver function test increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 1c: Multiple ascending dose (MAD) Placebo	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Investigations			
Liver function test increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
Liver function test increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Gastroesophageal reflux disease subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 1c: MAD Cohort 4	Part 1c: MAD Cohort 5	Part 2: POM Cohort 1
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
Liver function test increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
Liver function test increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Malignant melanoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 2: POM Cohort 5		
Total subjects affected by serious			

adverse events			
subjects affected / exposed	0 / 6 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Investigations			
Liver function test increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cellulitis			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part 3: Cohort B	Part 3: Cohort A	Parts 1a and 1b: Single ascending dose (SAD) Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 10 (90.00%)	22 / 32 (68.75%)	3 / 11 (27.27%)
General disorders and administration site conditions			
Catheter site bruise			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Catheter site erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Catheter site swelling			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	0	2	0
Fatigue			
subjects affected / exposed	1 / 10 (10.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Influenza like illness			

subjects affected / exposed	0 / 10 (0.00%)	5 / 32 (15.63%)	0 / 11 (0.00%)
occurrences (all)	0	7	0
Injection site erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Medical device site dermatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Medical device site rash			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Swelling face			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Heavy menstrual bleeding			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Menstrual disorder			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Intermenstrual bleeding subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 32 (6.25%) 2	0 / 11 (0.00%) 0
Dry throat subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	2 / 32 (6.25%) 3	0 / 11 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Blood triglycerides increased			

subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Platelet count decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Dental restoration failure			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Muscle strain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			

Palpitations subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 3	3 / 32 (9.38%) 7	2 / 11 (18.18%) 3
Lethargy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Lumbosacral radiculopathy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 32 (6.25%) 2	0 / 11 (0.00%) 0
Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Splenomegaly			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Lymphadenitis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Ear and labyrinth disorders			
Deafness subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Motion sickness subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Eye disorders			
Blepharitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Blepharospasm subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Conjunctivitis allergic subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Orbital oedema subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Visual impairment			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	0	2	0
Abdominal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 10 (10.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Dental caries			
subjects affected / exposed	0 / 10 (0.00%)	2 / 32 (6.25%)	0 / 11 (0.00%)
occurrences (all)	0	2	0
Diarrhoea			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Dry mouth			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Epigastric discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Gastritis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Gastroesophageal reflux disease			
subjects affected / exposed	2 / 10 (20.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	2	1	0
Gingival bleeding			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 10 (10.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	1	3	0
Toothache			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hepatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Alopecia			

subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Dermatitis contact			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Dermatitis allergic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 10 (0.00%)	2 / 32 (6.25%)	0 / 11 (0.00%)
occurrences (all)	0	2	0
Pruritus			
subjects affected / exposed	0 / 10 (0.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Rash vesicular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Thyroid disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Thyroid mass subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Limb discomfort subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 32 (0.00%) 0	0 / 11 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 32 (3.13%) 1	0 / 11 (0.00%) 0
Infections and infestations			

COVID-19			
subjects affected / exposed	1 / 10 (10.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Gastroenteritis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Mumps			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	2 / 10 (20.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	2	0	0
Periorbital cellulitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	3 / 32 (9.38%)	0 / 11 (0.00%)
occurrences (all)	0	3	0
Rhinitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	5 / 32 (15.63%)	0 / 11 (0.00%)
occurrences (all)	0	6	0
Urinary tract infection			
subjects affected / exposed	1 / 10 (10.00%)	3 / 32 (9.38%)	0 / 11 (0.00%)
occurrences (all)	2	6	0
Viral infection			
subjects affected / exposed	1 / 10 (10.00%)	1 / 32 (3.13%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Vaginal infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperlipidaemia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Increased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 32 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Part 3: Cohort C	Part 1a: SAD Cohort 3	Part 1a: SAD Cohort 4
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 30 (100.00%)	3 / 3 (100.00%)	5 / 6 (83.33%)
General disorders and administration site conditions			
Catheter site bruise			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Catheter site erythema			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 30 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Catheter site swelling			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			

subjects affected / exposed	4 / 30 (13.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	6	0	0
Fatigue			
subjects affected / exposed	9 / 30 (30.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	13	0	0
Influenza like illness			
subjects affected / exposed	5 / 30 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	9	0	0
Injection site erythema			
subjects affected / exposed	4 / 30 (13.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Malaise			
subjects affected / exposed	4 / 30 (13.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	6	0	0
Medical device site dermatitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Medical device site rash			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Pyrexia			
subjects affected / exposed	18 / 30 (60.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	35	0	0
Swelling face			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Reproductive system and breast disorders			
Heavy menstrual bleeding			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Menstrual disorder			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Intermenstrual bleeding			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 30 (13.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Dry throat			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	3 / 30 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Dysphonia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	11 / 30 (36.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	13	0	0

Aspartate aminotransferase increased			
subjects affected / exposed	9 / 30 (30.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	12	0	0
Blood triglycerides increased			
subjects affected / exposed	4 / 30 (13.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	6	0	0
Haemoglobin decreased			
subjects affected / exposed	3 / 30 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	5	0	0
Neutrophil count decreased			
subjects affected / exposed	6 / 30 (20.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	12	0	0
Platelet count decreased			
subjects affected / exposed	12 / 30 (40.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	17	0	0
Weight decreased			
subjects affected / exposed	7 / 30 (23.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	7	0	0
White blood cell count decreased			
subjects affected / exposed	7 / 30 (23.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	11	0	0
Injury, poisoning and procedural complications			
Dental restoration failure			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	1 / 30 (3.33%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Thermal burn			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			

subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders			
Palpitations			
subjects affected / exposed	3 / 30 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	5	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	6 / 30 (20.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	10	0	0
Hypoaesthesia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Headache			
subjects affected / exposed	14 / 30 (46.67%)	1 / 3 (33.33%)	4 / 6 (66.67%)
occurrences (all)	20	1	4
Lethargy			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Lumbosacral radiculopathy			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphadenopathy			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Neutropenia			

subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Splenomegaly			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Thrombocytopenia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Lymphadenitis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Blepharospasm			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			

subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Visual impairment subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 4	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 4	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Dental caries subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Dry mouth subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Dyspepsia subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Epigastric discomfort subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0

Flatulence			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	3 / 30 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Haemorrhoids			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Mouth ulceration			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Nausea			
subjects affected / exposed	5 / 30 (16.67%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	5	1	0
Toothache			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Vomiting			
subjects affected / exposed	3 / 30 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	3 / 30 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Hepatitis			
subjects affected / exposed	5 / 30 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	5	0	0
Skin and subcutaneous tissue disorders			

Blister			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Alopecia			
subjects affected / exposed	11 / 30 (36.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	11	0	0
Dermatitis contact			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Dermatitis allergic			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Eczema			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Petechiae			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	8 / 30 (26.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	9	0	0
Rash			
subjects affected / exposed	7 / 30 (23.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	9	0	0
Rash vesicular			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Endocrine disorders			
Thyroid disorder			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Thyroid mass			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 30 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	6	0	0
Back pain			
subjects affected / exposed	5 / 30 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	9	0	0
Joint swelling			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Limb discomfort			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			
subjects affected / exposed	1 / 30 (3.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	7 / 30 (23.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	11	0	0
Neck pain			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Pain in extremity			

subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 3	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Infections and infestations			
COVID-19			
subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Gastroenteritis			
subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Mumps			
subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Nasopharyngitis			
subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Periorbital cellulitis			
subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Respiratory tract infection			
subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Rhinitis			
subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Upper respiratory tract infection			
subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 5	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Urinary tract infection			
subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Viral infection			
subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Vaginal infection			
subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0

Metabolism and nutrition disorders			
Hyperlipidaemia			
subjects affected / exposed	6 / 30 (20.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	10	0	0
Decreased appetite			
subjects affected / exposed	10 / 30 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	12	0	0
Hyperuricaemia			
subjects affected / exposed	3 / 30 (10.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Hypertriglyceridaemia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
Hypocalcaemia			
subjects affected / exposed	2 / 30 (6.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Increased appetite			
subjects affected / exposed	0 / 30 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Part 1a and 1b: SAD Cohort 2 (food effect)	Part 1a: SAD Cohort 1	Part 2: Proof-of-Mechanism (POM) Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 6 (50.00%)	1 / 3 (33.33%)	3 / 6 (50.00%)
General disorders and administration site conditions			
Catheter site bruise			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Catheter site erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Catheter site swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Chest discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Injection site erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Medical device site dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Medical device site rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Reproductive system and breast disorders			
Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Menstrual disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Intermenstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Dry throat subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Investigations			

Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood triglycerides increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Injury, poisoning and procedural complications			
Dental restoration failure subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Muscle strain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Thermal burn			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Tooth fracture subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Lethargy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Lumbosacral radiculopathy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Lymphadenopathy			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blepharospasm			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dental caries			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Epigastric discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatitis			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Rash vesicular subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Endocrine disorders			
Thyroid disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Thyroid mass subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Limb discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Neck pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mumps			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Periorbital cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Vaginal infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Metabolism and nutrition disorders			
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Increased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0

<b>Non-serious adverse events</b>	Part 1c: Multiple ascending dose (MAD) Placebo	Part 1a: SAD Cohort 5	Part 1a: SAD Cohort 6
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 10 (60.00%)	2 / 6 (33.33%)	3 / 6 (50.00%)
General disorders and administration site conditions			
Catheter site bruise subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Catheter site erythema subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Catheter site pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

Catheter site swelling			
subjects affected / exposed	1 / 10 (10.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Chest discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injection site erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Medical device site dermatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Medical device site rash			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Menstrual disorder subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Intermenstrual bleeding subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Dry throat subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Dental restoration failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thermal burn			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Tooth fracture subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 3	0 / 6 (0.00%) 0	1 / 6 (16.67%) 2
Lethargy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Lumbosacral radiculopathy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Lymphadenopathy			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphadenitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blepharospasm			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 10 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dental caries			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Epigastric discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 10 (10.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatitis			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 10 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Night sweats			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	1 / 10 (10.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Rash vesicular subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Endocrine disorders			
Thyroid disorder subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Thyroid mass subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Limb discomfort subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Neck pain			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mumps			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Periorbital cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 6 (16.67%)	2 / 6 (33.33%)
occurrences (all)	0	1	2
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Vaginal infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Metabolism and nutrition disorders			
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Increased appetite subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

<b>Non-serious adverse events</b>	Part 1c: MAD Cohort 1	Part 1c: MAD Cohort 2	Part 1c: MAD Cohort 3
Total subjects affected by non-serious adverse events subjects affected / exposed	5 / 6 (83.33%)	4 / 7 (57.14%)	2 / 7 (28.57%)
General disorders and administration site conditions			
Catheter site bruise subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Catheter site erythema subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Catheter site pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1

Catheter site swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injection site erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Medical device site dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Medical device site rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Menstrual disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Intermenstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Dry throat subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0

Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Dental restoration failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Thermal burn			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Tooth fracture subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	1 / 7 (14.29%) 1	1 / 7 (14.29%) 1
Lethargy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Lumbosacral radiculopathy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Lymphadenopathy			

subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blepharospasm			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dental caries			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	1 / 6 (16.67%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Epigastric discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	1 / 6 (16.67%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hepatitis			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 6 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Rash vesicular subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Endocrine disorders			
Thyroid disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Thyroid mass subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 7 (28.57%) 2	0 / 7 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Limb discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Neck pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Mumps			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Periorbital cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Vaginal infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Metabolism and nutrition disorders			
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Increased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0

<b>Non-serious adverse events</b>	Part 1c: MAD Cohort 4	Part 1c: MAD Cohort 5	Part 2: POM Cohort 1
Total subjects affected by non-serious adverse events subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	4 / 6 (66.67%)
General disorders and administration site conditions			
Catheter site bruise subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	1 / 6 (16.67%) 1
Catheter site erythema subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Catheter site pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

Catheter site swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Injection site erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Medical device site dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Medical device site rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Swelling face			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Menstrual disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Intermenstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0
Dry throat subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Dysphonia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Dental restoration failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thermal burn			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Tooth fracture subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	2 / 6 (33.33%) 2
Lethargy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Lumbosacral radiculopathy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Lymphadenopathy			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blepharospasm			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dental caries			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Epigastric discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatitis			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Rash vesicular subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Endocrine disorders			
Thyroid disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Thyroid mass subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Limb discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Neck pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mumps			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Periorbital cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	3
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Vaginal infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Metabolism and nutrition disorders			
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Increased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

<b>Non-serious adverse events</b>	Part 2: POM Cohort 2	Part 2: POM Cohort 3	Part 2: POM Cohort 4
Total subjects affected by non-serious adverse events subjects affected / exposed	4 / 6 (66.67%)	5 / 6 (83.33%)	4 / 7 (57.14%)
General disorders and administration site conditions			
Catheter site bruise subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Catheter site erythema subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Catheter site pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0

Catheter site swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Injection site erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Medical device site dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Medical device site rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Vessel puncture site haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0
Menstrual disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Intermenstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Dry throat subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	2 / 7 (28.57%) 2
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	1 / 7 (14.29%) 2

Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 7 (14.29%)
occurrences (all)	1	1	2
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 7 (14.29%)
occurrences (all)	1	1	2
Blood triglycerides increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Dental restoration failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Thermal burn			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Tooth fracture subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	2 / 7 (28.57%) 2
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 2
Headache subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	2 / 7 (28.57%) 3
Lethargy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Lumbosacral radiculopathy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Lymphadenopathy			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Splenomegaly			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blepharospasm			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Orbital oedema subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Visual impairment subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Dental caries subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 6 (33.33%) 2	1 / 7 (14.29%) 3
Dry mouth subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Dyspepsia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0

Epigastric discomfort			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	2
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hepatitis			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Petechiae			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Rash vesicular subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Endocrine disorders			
Thyroid disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Thyroid mass subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Back pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Limb discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Myalgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Neck pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Mumps			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Periorbital cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Vaginal infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Metabolism and nutrition disorders			
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Increased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0

<b>Non-serious adverse events</b>	Part 2: POM Cohort 5		
Total subjects affected by non-serious adverse events subjects affected / exposed	2 / 6 (33.33%)		
General disorders and administration site conditions			
Catheter site bruise subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Catheter site erythema subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Catheter site pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		

Catheter site swelling			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Chest discomfort			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Injection site erythema			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Medical device site dermatitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Medical device site rash			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Swelling face			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Vessel puncture site haematoma			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)  Menstrual disorder subjects affected / exposed occurrences (all)  Intermenstrual bleeding subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Dry throat subjects affected / exposed occurrences (all)  Epistaxis subjects affected / exposed occurrences (all)  Dysphonia subjects affected / exposed occurrences (all)  Oropharyngeal pain subjects affected / exposed occurrences (all)  Rhinitis allergic subjects affected / exposed occurrences (all)  Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  1 / 6 (16.67%) 2  0 / 6 (0.00%) 0		

Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2		
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Blood triglycerides increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Weight decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Injury, poisoning and procedural complications			
Dental restoration failure subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Contusion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Muscle strain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Thermal burn			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Tooth fracture</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p>		
<p>Cardiac disorders</p> <p>Palpitations</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 6 (0.00%)</p> <p>0</p>		
<p>Nervous system disorders</p> <p>Dizziness</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hypoaesthesia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Headache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Lethargy</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Lumbosacral radiculopathy</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Presyncope</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p>		
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Iron deficiency anaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Lymphadenopathy</p>	<p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p>		

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Splenomegaly			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Lymphadenitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Motion sickness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Blepharospasm			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Conjunctival haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Conjunctivitis allergic			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Orbital oedema			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Visual impairment			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dental caries			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Epigastric discomfort			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Gastritis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Haemorrhoids			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Mouth ulceration			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hepatitis			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dermatitis contact			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dermatitis allergic			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Eczema			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Petechiae			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Rash vesicular subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Endocrine disorders Thyroid disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Thyroid mass subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Back pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Joint swelling subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Limb discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Muscular weakness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Myalgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Neck pain			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Mumps			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Periorbital cellulitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Viral infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Vaginal infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Metabolism and nutrition disorders			
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Decreased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Increased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 August 2017	Additional visits added to study schedule; clarification of the number of MAD cohorts
02 January 2019	Addition of study Part 3; update to study title
21 June 2019	Updated for participants in Part 3 to continue post-study NUC therapy; increase in overall sample size
21 May 2020	Updates to eligibility criteria

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported